Literature DB >> 7707540

Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus.

L O Arthur1, J W Bess, R G Urban, J L Strominger, W R Morton, D L Mann, L E Henderson, R E Benveniste.   

Abstract

Macaques immunized with uninfected human cells have been shown to be protected from challenge with simian immunodeficiency virus (SIV) propagated in human cells. To identify the potential antigens involved in this protection, macaques were immunized with uninfected human cells, sucrose density gradient-purified culture fluid from uninfected human cells (mock virus), beta-2 microglobulin (beta 2M), immunoaffinity-purified HLA class I and class II proteins from these human cells, and adjuvant. Although all macaques immunized with beta 2M and HLA class I developed high antibody titers to beta 2M, these animals were not protected from a subsequent challenge with infectious SIV grown in human cells. In contrast, the macaques immunized with class II protein (HLA-DR) and mock virus developed antibodies to class II protein and were protected from the intravenous infectious virus challenge. The class II protein- and mock virus-immunized animals which were protected from challenge were given boosters of the appropriate antigen and challenged with the same SIV propagated in macaque cells. All animals became infected, indicating that the protection seen with human class II protein did not extend to protection from infection with SIV containing macaque class II proteins. Since the virus released from SIV-infected macaque cells would contain macaque class II proteins, our results suggest that the initial SIV infected was completely prevented. In addition, the lack of protection from challenge with SIV propagated in macaque cells provided strong evidence that the protection was due to an immune response to the cellular proteins and not to epitopes cross-reactive between class II proteins and the viral proteins, since the identical virus proteins were present in both challenge stocks. These results are the first demonstration that immunization with a purified cellular protein can protect from virus infection.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7707540      PMCID: PMC189013     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  56 in total

1.  THE PREPARATION OF I-131-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY.

Authors:  F C GREENWOOD; W M HUNTER; J S GLOVER
Journal:  Biochem J       Date:  1963-10       Impact factor: 3.857

2.  Incorporation of HLA antigens into the envelope of RNA tumor viruses grown in human cells.

Authors:  J Azocar; M Essex
Journal:  Cancer Res       Date:  1979-09       Impact factor: 12.701

3.  Purification and characterization of class II histocompatibility antigens from a homozygous human B cell line.

Authors:  J C Gorga; V Horejsí; D R Johnson; R Raghupathy; J L Strominger
Journal:  J Biol Chem       Date:  1987-11-25       Impact factor: 5.157

4.  Direct identification of class II histocompatibility DR proteins in preparations of human T-cell lymphotropic virus type III.

Authors:  L E Henderson; R Sowder; T D Copeland; S Oroszlan; L O Arthur; W G Robey; P J Fischinger
Journal:  J Virol       Date:  1987-02       Impact factor: 5.103

5.  Nonrandom association of cellular antigens with HTLV-III virions.

Authors:  J A Hoxie; T P Fitzharris; P R Youngbar; D M Matthews; J L Rackowski; S F Radka
Journal:  Hum Immunol       Date:  1987-01       Impact factor: 2.850

6.  Selective incorporation of H-2 antigenic determinants into Friend virus particles.

Authors:  J E Bubbers; F Lilly
Journal:  Nature       Date:  1977-03-31       Impact factor: 49.962

7.  Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines.

Authors:  L O Arthur; J W Bess; R C Sowder; R E Benveniste; D L Mann; J C Chermann; L E Henderson
Journal:  Science       Date:  1992-12-18       Impact factor: 47.728

8.  Association of human T-cell leukaemia/lymphoma virus with the Tac antigen marker for the human T-cell growth factor receptor.

Authors:  Z Lando; P Sarin; M Megson; W C Greene; T A Waldman; R C Gallo; S Broder
Journal:  Nature       Date:  1983 Oct 20-26       Impact factor: 49.962

9.  Specific selection of host cell glycoproteins during assembly of murine leukaemia virus and vesicular stomatitis virus: presence of Thy-1 glycoprotein and absence of H-2, Pgp-1 and T-200 glycoproteins on the envelopes of these virus particles.

Authors:  J Calafat; H Janssen; P Démant; J Hilgers; J Závada
Journal:  J Gen Virol       Date:  1983-06       Impact factor: 3.891

10.  Identification of homologous regions in human immunodeficiency virus I gp41 and human MHC class II beta 1 domain. I. Monoclonal antibodies against the gp41-derived peptide and patients' sera react with native HLA class II antigens, suggesting a role for autoimmunity in the pathogenesis of acquired immune deficiency syndrome.

Authors:  H Golding; F A Robey; F T Gates; W Linder; P R Beining; T Hoffman; B Golding
Journal:  J Exp Med       Date:  1988-03-01       Impact factor: 14.307

View more
  41 in total

1.  Incorporation of HLA-DR into the envelope of human immunodeficiency virus type 1 in vivo: correlation with stage of disease and presence of opportunistic infection.

Authors:  S D Lawn; S T Butera
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

2.  Protection of Macaca nemestrina from disease following pathogenic simian immunodeficiency virus (SIV) challenge: utilization of SIV nucleocapsid mutant DNA vaccines with and without an SIV protein boost.

Authors:  R J Gorelick; R E Benveniste; J D Lifson; J L Yovandich; W R Morton; L Kuller; B M Flynn; B A Fisher; J L Rossio; M Piatak; J W Bess; L E Henderson; L O Arthur
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  Lessons in nonhuman primate models for AIDS vaccine research: from minefields to milestones.

Authors:  Jeffrey D Lifson; Nancy L Haigwood
Journal:  Cold Spring Harb Perspect Med       Date:  2012-06       Impact factor: 6.915

4.  Immunization with recombinant HLA classes I and II, HIV-1 gp140, and SIV p27 elicits protection against heterologous SHIV infection in rhesus macaques.

Authors:  Andreas Mörner; Marianne Jansson; Evelien M Bunnik; Jørgen Schøller; Robert Vaughan; Yufei Wang; David C Montefiori; Nel Otting; Ronald Bontrop; Lesley A Bergmeier; Mahavir Singh; Richard T Wyatt; Hanneke Schuitemaker; Gunnel Biberfeld; Rigmor Thorstensson; Thomas Lehner
Journal:  J Virol       Date:  2011-04-13       Impact factor: 5.103

Review 5.  Inhibition of HIV-1 entry by antibodies: potential viral and cellular targets.

Authors:  S Phogat; R T Wyatt; G B Karlsson Hedestam
Journal:  J Intern Med       Date:  2007-07       Impact factor: 8.989

6.  Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins.

Authors:  J L Rossio; M T Esser; K Suryanarayana; D K Schneider; J W Bess; G M Vasquez; T A Wiltrout; E Chertova; M K Grimes; Q Sattentau; L O Arthur; L E Henderson; J D Lifson
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

Review 7.  Virus maturation by budding.

Authors:  H Garoff; R Hewson; D J Opstelten
Journal:  Microbiol Mol Biol Rev       Date:  1998-12       Impact factor: 11.056

8.  Two-dimensional gel-based approaches for the assessment of N-Linked and O-GlcNAc glycosylation in human and simian immunodeficiency viruses.

Authors:  David R M Graham; Megan J Mitsak; Steven T Elliott; Dawn Chen; Stephen A Whelan; Gerald W Hart; Jennifer E Van Eyk
Journal:  Proteomics       Date:  2008-12       Impact factor: 3.984

9.  Cytoskeletal proteins bound to heat-shock protein 70 may elicit resistance to simian immunodeficiency virus infection of CD4(+) T cells.

Authors:  Lesley A Bergmeier; Kaboutar Babaahmady; Jeffrey Pido-Lopez; Kate J Heesom; Charles G Kelly; Thomas Lehner
Journal:  Immunology       Date:  2009-11-25       Impact factor: 7.397

10.  Vaccine protection by a triple deletion mutant of simian immunodeficiency virus.

Authors:  M S Wyand; K H Manson; M Garcia-Moll; D Montefiori; R C Desrosiers
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.